Conning Inc. Cuts Stake in Humana Inc. (NYSE:HUM)

Conning Inc. lessened its stake in Humana Inc. (NYSE:HUM) by 5.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 915 shares of the insurance provider’s stock after selling 52 shares during the quarter. Conning Inc.’s holdings in Humana were worth $232,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of HUM. FNY Investment Advisers LLC increased its holdings in shares of Humana by 6,647.5% in the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock worth $6,916,000 after purchasing an additional 26,856 shares in the last quarter. Retirement Systems of Alabama increased its holdings in Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after buying an additional 192,801 shares in the last quarter. PDT Partners LLC raised its position in Humana by 190.0% in the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock worth $1,286,000 after buying an additional 2,660 shares during the last quarter. Secure Asset Management LLC bought a new position in Humana during the 4th quarter valued at about $244,000. Finally, Ontario Teachers Pension Plan Board boosted its holdings in shares of Humana by 6.5% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock valued at $371,705,000 after acquiring an additional 71,910 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on HUM. Morgan Stanley boosted their price objective on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Barclays increased their price target on Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, January 22nd. TD Cowen lifted their price objective on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Piper Sandler increased their target price on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Finally, Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $297.68.

Humana Trading Down 2.0 %

Shares of Humana stock opened at $274.06 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The company has a fifty day moving average of $274.21 and a 200 day moving average of $298.14. The company has a market capitalization of $33.00 billion, a P/E ratio of 24.27, a P/E/G ratio of 2.11 and a beta of 0.56. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.

Insider Transactions at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.32% of the company’s stock.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.